Search Results - "Bonifacio, Maria Joao"
-
1
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys
Published in European journal of pharmacology (05-02-2021)“…Opicapone is a third generation nitrocatechol catechol-O-methyltransferase inhibitor that has received regional market approval for use as adjunctive therapy…”
Get full text
Journal Article -
2
Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide
Published in Neuropharmacology (01-02-2015)“…This study aimed at evaluating the effects of eslicarbazepine, carbamazepine (CBZ), oxcarbazepine (OXC) and lacosamide (LCM) on the fast and slow inactivated…”
Get full text
Journal Article -
3
Metabolism and disposition of zamicastat in rats
Published in Xenobiotica (10-10-2024)“…The metabolism and disposition of zamicastat, a reversible dopamine β-hydroxylase (DβH) inhibitor, developed for treatment of Pulmonary Arterial Hypertension…”
Get full text
Journal Article -
4
Absorption, metabolism and excretion of opicapone in human healthy volunteers
Published in British journal of clinical pharmacology (01-10-2022)“…Aims The absorption, metabolism and excretion of opicapone (2,5‐dichloro‐3‐(5‐[3,4‐dihydroxy‐5‐nitrophenyl]‐1,2,4‐oxadiazol‐3‐yl)‐4,6‐dimethylpyridine…”
Get full text
Journal Article -
5
Organ-Specific Overexpression of Renal LAT2 and Enhanced Tubular l-DOPA Uptake Precede the Onset of Hypertension
Published in Hypertension (Dallas, Tex. 1979) (01-10-2003)“…ABSTRACT—Spontaneously hypertensive rats (SHR) might have increased renal production of dopamine. l-3,4-Dihydroxyphenylalanine (l-DOPA) uptake in renal…”
Get full text
Journal Article -
6
Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration
Published in Neuropharmacology (01-12-2018)“…The aim of the study was to clarify the dose response for inhibition of catechol-O-methyltransferase (COMT) by opicapone, a third generation COMT inhibitor,…”
Get full text
Journal Article -
7
Opicapone: a short lived and very long acting novel catechol‐O‐methyltransferase inhibitor following multiple dose administration in healthy subjects
Published in British journal of clinical pharmacology (01-11-2013)“…Aims The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol‐O‐methyltransferase (S‐COMT)…”
Get full text
Journal Article -
8
A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat
Published in Neuropharmacology (01-10-2017)“…Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor that emerged to fulfil the need of a safer and more efficacious COMT inhibitor. The present…”
Get full text
Journal Article -
9
Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects: Prediction of Slow Enzyme–Inhibitor Complex Dissociation of a Short-Living and Very Long-Acting Inhibitor
Published in Clinical pharmacokinetics (01-02-2013)“…Background and Objectives Opicapone is a novel catechol- O -methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability,…”
Get full text
Journal Article -
10
Effect of opicapone multiple‐dose regimens on levodopa pharmacokinetics
Published in British journal of clinical pharmacology (01-03-2017)“…Aims To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered…”
Get full text
Journal Article -
11
Carbamazepine aggravates absence seizures in two dedicated mouse models
Published in Pharmacological reports (01-10-2015)“…The aim of this study was to evaluate the effect of carbamazepine (CBZ) upon chemically induced absence seizures and in a genetic absence seizures model in the…”
Get more information
Journal Article -
12
N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor
Published in Drug metabolism and disposition (01-12-2013)“…Etamicastat [(R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione hydrochloride] is a reversible dopamine-β-hydroxylase inhibitor that…”
Get full text
Journal Article -
13
Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: Comparison with nepicastat
Published in European journal of pharmacology (15-03-2015)“…The interaction of etamicastat, a novel peripherally acting dopamine-β-hydroxylase (DBH) inhibitor, with the enzyme was studied using a classical kinetic…”
Get full text
Journal Article -
14
Performance of hydrophobic interaction ligands for human membrane-bound catechol-O-methyltransferase purification
Published in Journal of separation science (01-06-2013)“…Despite of membrane catechol‐O‐methyltransferase (MBCOMT, EC 2.1.1.6) physiological importance on catecholamines’ O‐methylation, no studies allowed their total…”
Get full text
Journal Article -
15
Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone
Published in Biochemical pharmacology (15-10-2009)“…The present study was designed to characterize pharmacodynamic and pharmacokinetic properties of nebicapone in rats and mice. Upon oral administration of…”
Get full text
Journal Article -
16
Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474
Published in British journal of pharmacology (01-05-2020)“…Background and Purpose In 2016, one person died and four others had mild‐to‐severe neurological symptoms during a phase I trial of the fatty acid amide…”
Get full text
Journal Article -
17
Synthesis and Biological Evaluation of a Novel Series of “Ortho-Nitrated” Inhibitors of Catechol-O-methyltransferase
Published in Journal of medicinal chemistry (15-12-2005)“…Novel regioisomeric “ortho-nitrated” catechols related to the catechol-O-methyltransferase (COMT) inhibitors BIA 3-202 3 and BIA 3-335 4 were synthesized and…”
Get full text
Journal Article -
18
Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug
Published in Brain (London, England : 1878) (01-02-2015)“…In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a major problem affecting a substantial fraction of patients. Many of the currently…”
Get full text
Journal Article -
19
Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase
Published in Journal of medicinal chemistry (22-04-2010)“…Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the…”
Get full text
Journal Article -
20
Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol- O-methyltransferase inhibitor
Published in European journal of pharmacology (24-01-2003)“…The present study reports the kinetic inhibitory profile of 1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone (BIA 3-202), a novel inhibitor of soluble…”
Get full text
Journal Article